

**KNL/SE/2024-25**

**19<sup>th</sup> February, 2025**

Online filing at: <https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp>

**To,**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, C-1, Block G**  
**Bandra-Kurla Complex, Bandra (E)**  
**Mumbai – 400051 (M.H.)**  
**Symbol: KRITINUT**

**Subject:- Submission of Machine Readable Form/Legible copy of Unaudited Standalone Financial Results of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2024.**

Dear Sir/ Ma'am,

This is in continuation of our letter no. KNL/SE/2024-25 dated 11<sup>th</sup> February, 2025 outcome of the Board meeting held on 11<sup>th</sup> February, 2025 and in reference to your email dated 17<sup>th</sup> February, 2025 requiring to submit machine readable form/legible copy of the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2024, in this respect we enclose herewith machine readable form/legible copy of the same.

You are requested to take note of the same in your records and disseminate on the Website of the exchange.

Thanking you,  
Yours Faithfully,  
**For, KRITI NUTRIENTS LIMITED**

**RAJ KUMAR BHAWSAR**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**  
**Encl: As aforesaid**

## **Kriti Nutrients Ltd.**

Corporate office:  
Brilliant Sapphire, 801-804, 8th Floor, Plot No. 10,  
Sch. 78-II, Vijay Nagar, Indore – 452 010 (M.P) INDIA

Registered Office:  
Mehta Chamber, 34 Siyaganj,  
Indore - 452007 (M.P) INDIA

Factory:  
Industrial Area No. 3, AB Road,  
Dewas (MP) INDIA

Tel: +91-731-271 9100  
E-mail: [info@kritiindia.com](mailto:info@kritiindia.com)  
CIN: L24132MP1996PLC011245



**Independent Auditors Review Report on Interim Quarterly Financial Statements of KRITI NUTRIENTS LIMITED for the quarter / nine month ended 31<sup>st</sup> December 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

To,  
The Board of Directors,  
**KRITI NUTRIENTS LIMITED**

- 1) We have reviewed the unaudited financial statements of **KRITI NUTRIENTS LIMITED** ("the Company") for the quarter / nine month ended **31<sup>st</sup> December 2024** ("the Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initiated by us for identification purposes.
- 2) This statement, which is the responsibility of the Company's Management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Standards 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial and accounting matters, and applying analytical and accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulation 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore  
Date: 11.02.2025

For **M Mehta & Company**  
Chartered Accountants  
Firm Registration No. 000957C



CA Nitin Bandi  
Partner  
M.N.400394  
UDIN: 25400394BMIXAB9454

**KRITI NUTRIENTS LIMITED**  
**CIN: L24132MP1996PLC011245**

Regd. Office:- "Mehta Chambers", 34, Siyaganj, Indore - 452 007 (M.P.)

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER 2024**

| Sr. No.   | Particulars  | Rs.in Lakhs (Except Earnings Per Share ) |                           |                           |                           |                           |                         |
|-----------|--|--|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
|           |  | Quarter Ended                            |                           |                           | Nine Months Ended         |                           | Year Ended              |
|           |  | 31.12.2024<br>(Unaudited)                | 30.09.2024<br>(Unaudited) | 31.12.2023<br>(Unaudited) | 31.12.2024<br>(Unaudited) | 31.12.2023<br>(Unaudited) | 31.03.2024<br>(Audited) |
| <b>1</b>  | <b>Income</b>  |  |                           |                           |                           |                           |                         |
|           | (i) Revenue From Operations  | 17292.13                                 | 17354.68                  | 16680.08                  | 53428.37                  | 51208.98                  | 68436.32                |
|           | (ii) Other Income  | 249.21                                   | 167.73                    | 144.07                    | 583.08                    | 327.81                    | 444.86                  |
|           | <b>Total Revenue (i+ii)</b>  | <b>17541.33</b>                          | <b>17522.41</b>           | <b>16824.14</b>           | <b>54011.45</b>           | <b>51536.79</b>           | <b>68881.18</b>         |
| <b>2</b>  | <b>Expenses</b>  |  |                           |                           |                           |                           |                         |
|           | (a) Cost of materials consumed   | 13580.14                                 | 14417.31                  | 13921.51                  | 43014.44                  | 41973.64                  | 55719.16                |
|           | (b) Purchases of Stock-in-Trade  | 513.30                                   | 696.13                    | 424.33                    | 1903.55                   | 1139.96                   | 1598.85                 |
|           | (c) Changes in inventories of finished goods,<br>Stock-in-Trade and work-in-progress       | 745.30                                   | (309.76)                  | (561.22)                  | 405.73                    | (77.08)                   | 51.95                   |
|           | (d) Employee benefits expense  | 437.50                                   | 445.08                    | 367.71                    | 1265.28                   | 1023.57                   | 1877.64                 |
|           | (e) Finance costs  | 14.64                                    | 11.54                     | 15.74                     | 38.99                     | 93.07                     | 139.03                  |
|           | (f) Depreciation and amortization expense  | 138.26                                   | 133.38                    | 117.03                    | 404.50                    | 343.63                    | 469.16                  |
|           | (g) Other expenses   | 910.84                                   | 875.08                    | 667.92                    | 2645.54                   | 2207.05                   | 2966.91                 |
|           | <b>Total expenses</b>  | <b>16339.98</b>                          | <b>16268.76</b>           | <b>14953.02</b>           | <b>49678.03</b>           | <b>46703.85</b>           | <b>62822.70</b>         |
| <b>3</b>  | <b>Profit/(loss) before exceptional items and tax (1-2)</b>                                | <b>1201.36</b>                           | <b>1253.65</b>            | <b>1871.12</b>            | <b>4333.42</b>            | <b>4832.94</b>            | <b>6058.48</b>          |
| <b>4</b>  | <b>Exceptional Items</b>   | -  | -                         | -                         | -                         | -                         | -                       |
| <b>5</b>  | <b>Profit/(loss) before tax (3+4)</b>  | <b>1201.36</b>                           | <b>1253.65</b>            | <b>1871.12</b>            | <b>4333.42</b>            | <b>4832.94</b>            | <b>6058.48</b>          |
| <b>6</b>  | <b>Tax expense</b>   |  |                           |                           |                           |                           |                         |
|           | (i) Current tax  | 377.11                                   | 291.73                    | 423.16                    | 1115.63                   | 1157.12                   | 1556.33                 |
|           | (ii) Deferred tax  | (0.42)                                   | 6.39                      | 28.54                     | 10.34                     | 22.56                     | (26.54)                 |
|           | <b>Total Tax Expenses(i+ii)</b>  | <b>376.69</b>                            | <b>298.12</b>             | <b>451.70</b>             | <b>1125.97</b>            | <b>1179.67</b>            | <b>1529.79</b>          |
| <b>7</b>  | <b>Net Profit / (Loss) after Tax for the period from continuing operations (5-6)</b>       | <b>824.66</b>                            | <b>955.53</b>             | <b>1419.42</b>            | <b>3207.45</b>            | <b>3653.27</b>            | <b>4528.69</b>          |
|           | <b>Profit / (Loss) for the period from discontinued operations</b>                         | -  | -                         | -                         | -                         | -                         | -                       |
|           | <b>Tax expense:</b>  |  |                           |                           |                           |                           |                         |
|           | (i) Current tax  | -  | -                         | -                         | -                         | -                         | -                       |
|           | (ii) Deferred tax  | -  | -                         | -                         | -                         | -                         | -                       |
|           | <b>Total Tax Expenses(i+ii)</b>  | -  | -                         | -                         | -                         | -                         | -                       |
| <b>8</b>  | <b>Net Profit / (Loss) after tax for the period from discontinued operations</b>           | -  | -                         | -                         | -                         | -                         | -                       |
| <b>9</b>  | <b>Net Profit / (Loss) after tax for the period (7+8)</b>                                  | <b>824.66</b>                            | <b>955.53</b>             | <b>1419.42</b>            | <b>3207.45</b>            | <b>3653.27</b>            | <b>4528.69</b>          |
| <b>10</b> | <b>Other Comprehensive Income</b>  |  |                           |                           |                           |                           |                         |
|           | <b>a</b> Items that will be reclassified to Profit and Loss                                |  |                           |                           |                           |                           |                         |
|           | (i) Fair Valuation of Investment through OCI   | (0.50)                                   | (7.98)                    | -                         | (5.97)                    | -                         | 6.28                    |
|           | (ii) Effective portion of Cash Flow Hedge  | -  | -                         | -                         | -                         | -                         | -                       |
|           | <b>b</b> Items that will not be reclassified to Profit and Loss                            |  |                           |                           |                           |                           |                         |
|           | (i) Remeasurement of defined benefits plans  | 0.38                                     | 0.38                      | (0.32)                    | 1.14                      | (1.92)                    | 1.52                    |
| <b>11</b> | <b>Total comprehensive Income for the Period (9+10)</b>                                    | <b>824.55</b>                            | <b>947.93</b>             | <b>1419.10</b>            | <b>3202.62</b>            | <b>3651.34</b>            | <b>4536.49</b>          |
| <b>12</b> | <b>Paid up Equity Share Capital (face Value Rs.1 Per Share)</b>                            | <b>501.04</b>                            | <b>501.04</b>             | <b>501.04</b>             | <b>501.04</b>             | <b>501.04</b>             | <b>501.04</b>           |
| <b>13</b> | <b>Earning per equity share of continuing operations (of Rs.1/- each)</b>                  |  |                           |                           |                           |                           |                         |
|           | (1) Basic  | 1.65                                     | 1.91                      | 2.83                      | 6.40                      | 7.29                      | 9.04                    |
|           | (2) Diluted  | 1.65                                     | 1.91                      | 2.83                      | 6.40                      | 7.29                      | 9.04                    |
| <b>14</b> | <b>Earning per equity share of discontinued operations (of Rs.1/- each)</b>                |  |                           |                           |                           |                           |                         |
|           | (1) Basic  | -  | -                         | -                         | -                         | -                         | -                       |
|           | (2) Diluted  | -  | -                         | -                         | -                         | -                         | -                       |
| <b>15</b> | <b>Earning per equity share of continuing and discontinued operations (of Rs.1/- each)</b> |  |                           |                           |                           |                           |                         |
|           | (1) Basic  | 1.65                                     | 1.91                      | 2.83                      | 6.40                      | 7.29                      | 9.04                    |
|           | (2) Diluted  | 1.65                                     | 1.91                      | 2.83                      | 6.40                      | 7.29                      | 9.04                    |

**Notes:-**

- The above results have been reviewed by the Audit Committee in its meeting held on 11th February, 2025 and taken on record by the Board of Directors in its meeting held on 11th February, 2025.
- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- The Company has only one Business Segment to be reported namely Oil Seed Extraction and Refining, as per Ind AS 108 Operating Segments.
- The Company had applied for and was allotted on July 27, 2024, 30,92,480 Warrants issued by Kriti Industries (India) Limited ("KIIL") at a price of Rs.158.50 each, each warrant carrying a right to apply and be allotted upon being fully paid up within a period of 18 months from date of allotment, one equity share of face value Re.1 of KIIL (including premium of Rs.157.50 each). [Subscription/Allotment money paid - Rs. 1225.40 lakhs, being 25% of the total warrant price]. Subsequent to the end of the quarter, and following early exercise of the option, on payment of the balance 75% payable [Rs. 1783.125 lakhs] in respect of 15,00,000 warrants, the Company was issued and allotted (on February 11, 2025) 15,00,000 equity shares of face value of Re.1 of KIIL at Rs.158.50 each (including premium of Rs.157.50 each). The Company retains the option in respect of the balance 15,92,480 warrants.
- The statutory auditors have expressed an unmodified audit opinion.
- The figures for quarter ended on 31st December 2024 and 31st December 2023 are balancing figures between the figure reviewed for nine months ended on 31st December 2024 and 31st December 2023 and the figure reviewed for six months ended on 30th September 2024 and 30th September 2023 respectively.

Place:- Indore  
Date:- 11th February 2025

For KRITI NUTRIENTS LIMITED

(SHIV SINGH MEHTA)  
Chairman & Managing Director  
DIN 00023523